<DOC>
	<DOCNO>NCT00269620</DOCNO>
	<brief_summary>This open-label prospective , multicenter , randomize trial compare continuation rate fourth cycle woman use either NuvaRing OrthoEvra . Five hundred woman recruit 9 center nationwide randomly assign use either NuvaRing OrthoEvra four month . Women must either pill recently stop pill relatively satisfied oral contraceptive use qualify enrollment . Two visit two phone call require .</brief_summary>
	<brief_title>PARIS PAtch RIng Study : A Trial Evaluate NuvaRing Versus OrthoEvra</brief_title>
	<detailed_description>The present study design primarily compare continuation rate three month use NuvaRing® OrthoEvra® woman previously use oral contraceptive . The study attempt evaluate possible choice woman content current recent method oral combine hormonal contraception would consider change method non-daily delivery system . Continuation rate demonstrate overall acceptance method woman find method convenient side effect likely continue use method . Sexual functioning another important aspect investigate . The Female Sexual Function Index ( FSFI ) administer participant along plan study questionnaire enrollment visit final visit . Additionally , study compare side effect , incidence bacterial vaginosis , direct measure acceptability two group . Efficacy three-month study period also evaluate ; however , since method highly effective study relatively short duration , study design large enough detect difference efficacy . This open-label , prospective , multicenter , randomize comparative trial conduct approximately 500 woman United States currently recently use combined oral contraceptive past experience use NuvaRing® OrthoEvra® . Subjects enrol provide informed consent , baseline blood pressure breast pelvic examination , negative endocervical test gonorrhea chlamydia . Participants randomize use either NuvaRing® OrthoEvra® four continuous cycle begin first day menses follow enrollment visit . Subjects contact research office phone confirm initiate method instruct . The researcher contact subject second week second cycle study medication . A final visit occur first week fourth cycle study medication ( sooner subject require request early discontinuation ) . An acceptability questionnaire administer subject 's final visit . This questionnaire modify questionnaire validate woman use NuvaRing® .</detailed_description>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Ortho Evra</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Currently recently ( within 3 month enrollment ) use oral contraceptive content use . In good general health contraindication combine hormonal contraceptive use ; premenopausal ; willing randomly assign use patch ring next 4 cycle . Willing forego use vaginal product anal intercourse study duration ; heterosexually active , must single partner least past 3 month plan change study participation . Known suspected pregnancy ; hypersensitivity NuvaRing OrthoEvra ; present use within 2 month liverenzymeinducing medication St. John 's Wort ; breastfeed currently within 60 day ; abortion delivery pregnancy 15 week great within 49 day ; abortion within 21 day 14 week less . Previous use patch ring contraception ; use injectable contraceptive within 6 month ; use investigational drug within 2 month ; plan pregnancy within 6 month . Diagnosis gonorrhea chlamydia screening , vaginal cervical abnormality would require colposcopy course study .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>contraceptive vaginal ring</keyword>
	<keyword>contraceptive patch</keyword>
	<keyword>oral contraceptive</keyword>
	<keyword>acceptability</keyword>
</DOC>